Journals / Journal of Neurological Sciences (Turkish) / 2013 / Cilt: 30 - Sayı: 1

Association of MDR1 Gene Polymorphism in Patients With Temporal Lobe Epilepsy

Temporal Lob Epilepsili Hastalarda MDR1 Gen Polimorfizmi İle İlişki

Pages
4–11
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Studies of mutationanalysis will play an important role to understand the pathophysiology of this disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: 30-40% of patients with epilepsy have resistance to medical treatment.
📊
Key Findings & Data:The majorgenetic mechanism postulated to underlie this resistance known as Multidrug resistance gene1 (MDR1), transports the drugs from intracellular to extracellular area.Methods: 103 temporal lobe epilepsy patients' (59 of the patients had mesial temporalsclerosis and 44 patients had cryptogenic etiology) and 174 healthy controls' samples wereevaluated for MDR1 gene (C3435T) polymorphism by polimerase chain reaction andrestriction fragment length polymorphisms.Results: In all patients and TLE patients without MTS, CT genotype was found to be lowerthan that of the control group (p=0,004 ve p=0,008).
💡
Conclusion & Impact:Studies of mutationanalysis will play an important role to understand the pathophysiology of this disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: 30-40% of patients with epilepsy have resistance to medical treatment. The majorgenetic mechanism postulated to underlie this resistance known as Multidrug resistance gene1 (MDR1), transports the drugs from intracellular to extracellular area.Methods: 103 temporal lobe epilepsy patients' (59 of the patients had mesial temporalsclerosis and 44 patients had cryptogenic etiology) and 174 healthy controls' samples wereevaluated for MDR1 gene (C3435T) polymorphism by polimerase chain reaction andrestriction fragment length polymorphisms.Results: In all patients and TLE patients without MTS, CT genotype was found to be lowerthan that of the control group (p=0,004 ve p=0,008). CT genotype was statistically lower inthe group without MTS than the group with MTS (p=0,0008). It is noted that the patients witha history of status epilepticus had significantly higher MDR1 gene TT genotype (p=0,027).There was no correlation between other clinical features and MDR1 genotype.Conclusions: Despite the difference of heterozygote CT genotype frequency in patient andcontrol populations, no correlation between clinical features and MDR1 genotype was found.This data may show diverse genetic background of different populations. Studies of mutationanalysis will play an important role to understand the pathophysiology of this disease.

Özet

Amaç: Epilepsi hastalarının %30-40'ı medikal tedaviye dirençlidir. İlaçları intrasellülerbölgeden ekstrasellüler bölgeye uzaklaştırarak etki eden çoklu ilaç direnci 1 geninin(multidrug resistans 1: MDR1), ilaç direncinden sorumlu en önemli genetik mekanizmaolduğu düşünülmektedir.Yöntem: 59'u mezyal temporal skleroz (MTS), 44'ü kriptojenik etiyolojili toplam 103temporal lob epilepsili hasta ve 174 sağlıklı kontrol örneklerinde polimeraz zincir reaksiyonuve restriksiyon fragmanı uzunluk polimorfizmi yöntemi ile MDR1 geni C3435Tpolimorfizminin varlığı ve hastalık bulgularının ilişkisi araştırılmıştır.Bulgular: Tüm hasta grubunda ve MTS olmayan hastalarda CT genotipi, kontrol grubunagöre anlamlı düzeyde düşük bulunmuştur (p=0,004 ve p=0,008). Her iki hasta grubukarşılaştırıldığında MTS olmayan grupta CT genotipinin daha düşük olduğu belirlenmiştir(p=0,0008). Status epileptikus öyküsü olan hastalarda anlamlı olarak TT genotipinin daha sıkolduğu dikkati çekmiştir (p=0,027). Diğer klinik bulgular ile MDR1 genotipi arasındabağlantı bulunmamıştır.Sonuç: Hasta ve kontrol grupları arasında heterozigot CT genotipinin sıklığı farklıbulunmakla birlikte, klinik özellikler açısından bir bağlantı kurulamamıştır. Bu durumtoplumsal farklılıkların yanısıra ilaca direnç mekanizmasında MDR geni dışında başkafaktörlerin de rol oynadığını düşündürmektedir. Mutasyon analizinin çalışılması bu hastalığınpatofizyolojisinin anlaşılmasında önem taşıyacaktır.

🔖

Cite This Article

BEBEK, N., ÇİNE, N., ÖZBEK, U., GÜRSES, C., SARGIN, G., GÖKYİĞİT, A., BAYKAN, B. (2022). Association of MDR1 Gene Polymorphism in Patients With Temporal Lobe Epilepsy. Journal of Neurological Sciences (Turkish), Cilt: 30 - Sayı: 1, 4–11. https://ajindex.com/articles/565205

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang 'a J, Indalo A, Of ori-Adj ei D, Price-Evans DA, McLeod HL. MDR 1 pharmacogenetics: f requency of the C3435T mutation in exon 26 is signif icantly inf luenced by ethnicity. Pharmacogenetics 2001; 11: 7-21
  2. Aronica E, Gorter JA, Jansen GH, van Veelen CW, van Rij en PC, Leenstra S, Ramkema M, Scheff er GL, Schep er RJ, Troost D. Exp ression and cellular distrtribution of multidrug transp orter p roteins in two maj or causes of medically intractable ep ilepsy: f ocal cortical dysp lasia and glioneuronal tumors. Neuroscience 2003; 118: 417-29
  3. Ban JJ, Jung KH, Chu K, Lee ST, Jeon D, Park KI, Moon HJ, Kim H, Kim S, Lee SK, Roh JK. Prof iles of multidrug resistance p rotein-1 in the p erip heral blood mononuclear cells of p atients with ref ractory ep ilepsy. PLoS One. 2012;7(5):e36985
  4. Bendayan R, Lee G, Bendayan M. Functional exp ression and localization of P-glycop rotein at the blood brain barrier. Microsc Res Tech 2002; 57: 365-80
  5. Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y. Polymorp hism of the MDR1/ABCB1 C3435T drug-transp orter and resistance to anticonvulsant drugs: a meta-analysis. Ep ilepsia 2009; 50(4): 898-903
  6. Chin-Chuan H, John Jen T, Chun-Jung L, Ming-Jen L, Horng-Huei L. Comp lex hap lotyp ic eff ects of the ABCB1 gene on ep ilepsy treatment resp onse. Pharmacogenomics 2005; 6(4): 411-7
  7. Demeule M, Regina A, Jodoin J, Lap lante A, Dagenais C, Berthelet F, Moghrabi A, Beliveau R. Drug transp ort to the brain: key roles f or the eff ux p ump P-glycop rotein in blood-brain barrier. Vasc Pharm 2002; 38: 339-48
  8. Dericioglu N, Babaoglu MO, Yasar U, Bal IB, Bozkurt A, Saygi S. Multidrug resistance in p atients undergoing resective ep ilepsy surgery is not associated with C3435T p olymorp hism in the ABCB1 (MDR1) gene. Ep ilepsy Res 2008; 80(1): 42-6
  9. Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, Mayberg MR, Bengez L, Janigro D. Overexp ression of multip l drug resistance genes in endotelial cells f rom p atients whit ref rectory ep ilepsy. Ep ilepsia 2001; 42(12): 1501-1506
  10. Hauser Wa, The natural history of drug resistant ep ilepsy ep idemiologic considerations. Ep ilepsy Res1992 Supp l. 5: 25-28
  11. Kim D W, Kim M, Lee SK, Kang R, Lee SY. Lack of association between C3435T nucleotide MDR1 genetic p olymorp hism and multidrug-resistant ep ilepsy. Seizure 2006; 15(5): 344-